StudyFinder

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase 2A, Double-blind, Randomized, Placebo-ControlledClinical Trial to Evaluate the Efficacy and Safety ofSaroglitazar Magnesium 4 mg Tablets for Treating NonalcoholicFatty Liver Disease (NAFLD) in Women WithPolycystic Ovary Syndrome (PCOS)

The purpose of this study is to evaluate the efficacy and safety of Saroglitazar Magnesium 4 mg Tablets once-daily in women with well characterized Polycystic ovary syndrome (PCOS) diagnosed with nonalcoholic fatty liver disease (NAFLD).

There will be 9 in person visits, various procedures will be completed such as a fibroscan, endometrial biopsy, blood draws and surveys. You will be randomly assigned by chance (like the flip of a coin) to receive either Saroglitazar 4 mg or placebo (inactive substance).

Yes
 
Jonathan Stine
Gloriany Rivas - at grivas@pennstatehealth.psu.edu or 717-531-0003, ext=320223
Medicine: Gastroenterology and Hepatology (HERSHEY)
 
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03617263
STUDY00020411
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults age >18-75 years old
NAFLD diagnosis
Stage 2 or 3 fibrosis
Exclusion Criteria:
causes of chronic liver disease other than NAFLD
pregnancy
Cirrhosis
Inability to provide informed consent
history of liver transplant
Digestive Systems & Liver Disease, Women's Health
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,